Editor replaced “eFFECTOR Therapeutics Reports Positive Zotatifin Phase 2 Data then Drops Anvil on their Shareholders” with this updated announcement coverage
(24/7 MARKET NEWS) – eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) was trading higher in this morning’s premarket, after reporting positive interim data updates from a Phase 2 study, but followed that with a second announcement of $7.5 Million registered at-the-market direct offering, bailing out any shorters who were about to feel some pain.
It was trading at new 2023 highs, but that party’s over, at least for a while, and I can almost picture the Company’s officers and board singing along to Jim Morrison “No one here gets out alive,” as they’re holding mock shareholder heads under water.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.